Parkinson's Disease Research

Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.

Parkinson's Disease Research Products Targets

Products for Parkinson's Disease Research - Page 10

  1. Cat.No. Product Name Information/Activity
  2. BCC7505 B2 115687-05-3 B2 chemical structure
  3. BCC6117 C3bot (154-182) 1246280-79-4 C3bot (154-182) chemical structure
  4. BCC1561 Etifoxine hydrochloride Etifoxine hydrochloride (HOE 36-801 hydrochlorid) is potentiator of GABAA receptor function in cultured neurons. Etifoxine hydrochloride chemical structure
  5. BCC3670 MOG (35-55) Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces strong T and B cell responses and is highly encephalitogenic. MOG (35-55) chemical structure
  6. BCC1028 Myelin Basic Protein (87-99) Major antigenic component implicated in the pathophysiology of multiple sclerosis Myelin Basic Protein (87-99) chemical structure
  7. BCC5862 Nogo-66 (1-40) 475221-20-6 Nogo-66 (1-40) chemical structure
  8. BCC7943 ONO 2506 Arundic acid (ONO-2506) is an astrocyte-modulating agent, which delays the expansion of cerebral infarcts by modulating the activation of astrocytes through inhibition of S-100β synthesis. Arundic acid (ONO-2506) has been developed as a therapeutic agent for stroke and Alzheimer’s disease. ONO 2506 chemical structure
  9. BCC5920 PLP (139-151) [SER140]-PLP(139-151) is a fragment of myelin proteolipid protein. PLP (139-151) chemical structure
  10. BCC6027 Prion Protein 106-126 (human) 148439-49-0 Prion Protein 106-126 (human) chemical structure
  11. BCC5999 TCS PrP Inhibitor 13 34320-83-7 TCS PrP Inhibitor 13 chemical structure

Items 91 to 100 of 752 total